IDEAYA Biosciences (NASDAQ:IDYA) reported fourth-quarter and full-year 2025 results on Tuesday, setting a definitive timeline for a high-stakes clinical readout that could transition the precision medicine firm into a commercial-stage biotech.
The South San Francisco-based company confirmed that the requisite 130 Progression-Free Survival (PFS) events have been reached in its OptimUM-02 trial.
The registrational Phase 2/3 study is evaluating the combination of darovasertib and crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma.
Topline results are now expected by the last week of March 2026, a milestone investors view as the primary catalyst for a potential accelerated approval filing with the FDA.
In an industry often plagued by capital crunches, IDEAYA reported a formidable financial position, ending 2025 with $1.05 billion in cash, cash equivalents, and marketable securities.
Bolstered by a $210 million upfront payment from its 2025 licensing deal with Servier, the company reaffirmed that its current war chest is sufficient to fund operations into 2030.